Doxapram

Doxapram (HCl) is a central nervous system stimulant and is used to stimulate respiration in post-anesthesia, chronic pulmonary disease etc. Doxapram stimulates an increase in tidal volume, and respiratory rate. Administered intravenously.

Doxapram is primarily indicated in conditions like COPD Associated with Acute hypercapnia, Respiratory Depression postanesthetic, Drug-induced CNS depression.

Doxapram is contraindicated in conditions like Cerebral edema, Epilepsy, Hypertension, Hyperthyroidism, Head injury, Pheochromocytoma, Convulsions ,Obstructive airway disease, Heart disease, Cerebrovascular accident, Coronary artery disease, Hypersensitivity, Neonates.

Adverse reactions reported coincident with the administration of doxapram include:

Doxapram should not be used in conjunction with mechanical ventilation. Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of kernicterus, particularly in small preterm infants. There have been rare reports of deaths, primarily in preterm infants, associated with exposure to excessive amounts of benzyl alcohol. The amount of benzyl alcohol from medications is usually considered negligible compared to that received in flush solutions containing benzyl alcohol. Administration of high dosages of medications containing this preservative must take into account the total amount of benzyl alcohol administered. The amount of benzyl alcohol at which toxicity may occur is not known. If the patient requires more than the recommended dosages or other medications containing this preservative, the practitioner must consider the daily metabolic load of benzyl alcohol from these combined sources. (See PRECAUTIONS , Pediatric Use. )

Doxapram should not be used in conjunction with mechanical ventilation. Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of kernicterus, particularly in small preterm infants. There have been rare reports of deaths, primarily in preterm infants, associated with exposure to excessive amounts of benzyl alcohol. The amount of benzyl alcohol from medications is usually considered negligible compared to that received in flush solutions containing benzyl alcohol. Administration of high dosages of medications containing this preservative must take into account the total amount of benzyl alcohol administered. The amount of benzyl alcohol at which toxicity may occur is not known. If the patient requires more than the recommended dosages or other medications containing this preservative, the practitioner must consider the daily metabolic load of benzyl alcohol from these combined sources. (See PRECAUTIONS , Pediatric Use. )

0.021 to 0.057 mg/kg.min (0.039 (0.039)) As recommended. IV — As Required

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS , General ). In patients who have received neuromuscular blocking agents, doxapram may temporarily mask the residual effects of these drugs. In patients who have received general anesthesia utilizing a volatile agent known to sensitize the myocardium to catecholamines, administration of doxapram should be delayed until the volatile agent has been excreted in order to lessen the potential for arrhythmias, including ventricular tachycardia and ventricular fibrillation (see WARNINGS ). There may be an interaction between doxapram and aminophylline and between doxapram and theophylline manifested by increased skeletal muscle activity, agitation, and hyperactivity.

Inj Store Below 40°C. Do not Freeze.